Vol. 1, Issue 2, Part A (2019)

Background: Diabetes mellitus (DM) is one of the major non-communicable diseases with increasing prevalence in both the developed and developing world. The present study was conducted to assess efficacy and safety of Rosuvastatin, Atorvastatin and Pravastatin among dyslipidemic diabetic patients. Atorvastatin documented to be the most potent statin at reducing LDLC levels. Alternatively, pravastatin which is available at the higher doses of 20 mg and 40 mg is found to be slightly less effective; the main reason for its prescription in patients is put down to its hydrophilic properties which make it more tolerable to patients with greater risk factors in addition to CVD. The present study was conducted to assess efficacy and safety of Rosuvastatin, Atorvastatin and Pravastatin among dyslipidemic diabetic patients.
Materials and Methods: The present study comprised of 60 diabetic patients of both genders. All were informed regarding the study and their written consent was obtained.
Data such as name, age, sex, height, weight, and BMI was recorded. Patients were divided into 3 groups of 20 each. Group I received 40 mg Atorvastatin, group II received 10 mg Rosuvastatin and group III received 20 mg Pravastatin. Lifestyle habits like smoking and alcohol intake, type of DM, its duration, and presence of hypertension was recorded. Fasting blood glucose, glycated hemoglobin (HbA1C), total cholesterol, HDL and LDL cholesterol levels, triglycerides, creatine kinase level, serum creatinine, bilirubin, LFTs, GGT, and serum albumin, microalbuminuria and macroalbuminuria was recorded. Data thus obtained were subjected to statistical analysis. P value < 0.05 was considered significant.
Result: In Group ‘A’ the mean difference of Total Cholesterol between baselines versus after 6 months was 84.43 mg/dl, 66.98 mg/dl and 54.29 mg/dl in Group B and Group C respectively. The mean difference of Triglycerides between baselines versus after 6 months was 67.08 mg/dl in Group A, 41.99 mg/dl in Group B and 39.08 mg/dl in Group C. The mean difference of HDL between baselines versus after 6 months was 12.08 mg/dl in Group A, 12.31 mg/dl in Group B and 11.19 mg/dl in Group C. The mean difference of LDL between baseline versus after 6 months was 81.6 mg/dl in Group A, 69.8 mg/dl in Group B and 35.88 mg/dl in Group C. The mean difference of VLDL between baselines versus after 6 months was 15.03 mg/dl in Group A, 9.64 mg/dl in Group B and 9.45 mg/dl in Group C.
Conclusion: The present study confirmed that rosuvastatin therapy in commonly prescribed doses is the most effective statin for low-density lipoprotein cholesterol goal achievement and for improving the lipid profile in hypercholesterolemic diabetic patients with and without MetS.